125518-48-1 Usage
Description
5-Bromothiazolidine-2,4-dione is a light yellow solid that serves as a key intermediate in the synthesis of various therapeutic Thiazolidine derivatives. These derivatives have demonstrated potential applications in the pharmaceutical industry due to their diverse biological activities.
Uses
Used in Pharmaceutical Industry:
5-Bromothiazolidine-2,4-dione is used as a synthetic intermediate for the development of Thiazolidine derivatives, which possess a range of therapeutic properties. These derivatives are being explored for their potential applications in treating various medical conditions, making 5-Bromothiazolidine-2,4-dione a valuable compound in the pharmaceutical sector.
Used in Chemical Synthesis:
As a light yellow solid, 5-Bromothiazolidine-2,4-dione is also used in chemical synthesis processes to create a variety of compounds with different applications. Its unique chemical properties allow it to be a versatile building block in the development of new materials and products across various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 125518-48-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,5,5,1 and 8 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 125518-48:
(8*1)+(7*2)+(6*5)+(5*5)+(4*1)+(3*8)+(2*4)+(1*8)=121
121 % 10 = 1
So 125518-48-1 is a valid CAS Registry Number.
125518-48-1Relevant articles and documents
CRBN LIGANDS AND USES THEREOF
-
Paragraph 00527-00529, (2019/08/20)
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CRBN, and the treatment of CRBN-mediated disorders.
5-[(1- and 2-naphthalenyl) sulfonyl]-2,4-thiazolidinediones and derivatives thereof
-
, (2008/06/13)
Disclosed herein are 1- or 2-thio, thiomethylene, and sulfonylnaphthalene derivatives of formulas I and II STR1 or a pharmaceutically acceptable catonic salt thereof, wherein n is 0 or 1 R5 is hydrogen, bromo, chloro, trifluoromethyl or difluoroethyl; R6 is hydrogen, hydroxy, methoxy or ethoxy; and R7 is hydrogen or R7 and R6 are both methyl or ethyl carbonate, provided that, when S(O)2 is in the 2 position of the naphthalene ring, R5, R6 and R7 are each hydrogen. The disclosed compounds possess blood-glucose lowering actions and are useful in the treatment of diabetes mellitus.